[Hematological stability under ubenimex monotherapy in a patient with acute myelogenous leukemia developing marrow karyotypic changes during the course].
We encountered a 71-year-old female with acute myelogenous leukemia (AML, M1), who maintained a steady hematological state for 22 months under ubenimex monotherapy. At the first medical examination in our hospital, the marrow cellularity was approximately 40% containing leukemic myeloblasts of 41.4% in the total nucleated cells, and the marrow cytogenetic study revealed 47, XX, + 8 in 13 of 20 cells analyzed. Nineteen months later, the bone marrow showed definite hypoplasia with leukemic blasts of 39.8% and chromosome finding of 46, XX, ins (10;?) (q11;?) in all cells analyzed. During the course, the patient has been doing well without transfusion of red blood cells or platelets.
Shimosegawa
K
K
Hematology Division, School of Medicine Iwate Medical University, Japan.
Ono
Y
Y
Sugawara
T
T
Numaoka
H
H
Oikawa
H
H
Ito
S
S
Utsugisawa
T
T
Murai
K
K
Narigasawa
Y
Y
Miyairi
Y
Y
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001854:Bone Marrow Cells; D002879:Chromosomes, Human, Pair 10; D002898:Chromosomes, Human, Pair 8; D005260:Female; D006801:Humans; D007621:Karyotyping; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D016254:Mutagenesis, Insertional; D014314:Trisomy
D000903:Antibiotics, Antineoplastic; D007930:Leucine; C012211:ubenimex